エドガーで原本を確認する
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission file number: 000-56663
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
SUBMITTED HEREWITH
Exhibits:
|
Exhibit |
Description |
|
News Release dated February 10, 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
BIOHARVEST SCIENCES INC. |
|
|
(Registrant) |
|
|
|
|
Date: February 10, 2025 |
/s/ David Ryan |
|
|
Name: David Ryan |
|
|
Title: Vice-President, Investor Relations & Secretary |
BioHarvest Sciences Announces Voluntary Delisting from CSE
Vancouver, British Columbia and Rehovot, Israel – February 10, 2025 - BioHarvest Sciences Inc., (Nasdaq: BHST) (CSE: BHSC) (FSE: 8MV0) (“BioHarvest” or “the Company”), a company pioneering its patented Botanical Synthesis technology process, today announced that that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the Nasdaq Global Market. The common shares will continue to trade on the Nasdaq under the symbol “BHST”.
The company believes that the trading volume of its shares on the CSE no longer justifies the expenses, administrative efforts, and regulatory burdens required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its common shares on the Nasdaq and ultimately benefit the long-term liquidity and shareholder value of the company. For these reasons, BioHarvest’s management team and Board of Directors have made the decision to voluntarily delist from the CSE, consolidating the trading of its shares to Nasdaq. All shareholders can continue trading BioHarvest’s shares on Nasdaq under the symbol “BHST”.
The Company is grateful to the CSE for providing its initial opportunity to access public markets.
It is expected that the close of business on Friday, February 14, 2025, will be the final trading day for BioHarvest on the CSE.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us